Lartruvo olaratumab regulatory update

EMA’s CHMP recommended conditional approval of Lartruvo olaratumab from Eli Lilly in combination with doxorubicin to treat advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery. As part of conditional approval, Lilly will be required to provide data from the Phase III ANNOUNCE trial comparing Lartruvo plus doxorubicin vs. doxorubicin alone in about 460 patients with advanced unresectable or metastatic STS not amenable to curative treatment with surgery or radiotherapy. Lilly said the trial has completed enrollment. Lartruvo is a human IgG1 mAb targeting platelet derived growth factor receptor A ( PDGFRA; PDGFR2; CD140A). ...